Promega Expands Forensic Portfolio with Distribution Agreement for NimaGen’s IDseek® MPS Library Prep Kits
14.4.2026 13:01:00 CEST | Business Wire | Press release
Agreement adds STR, SNP, microhaplotype and mitochondrial DNA MPS kits to Promega forensic product lineup
Forensic casework laboratories will now have access to NimaGen’s IDseek® massively parallel sequencing (MPS) kit portfolio through Promega Corporation, following a distribution agreement announced today between the two companies. The IDseek® line is powered by NimaGen’s patented Reverse Complement PCR (RC-PCR) technology to deliver the sensitivity and specificity required for challenging casework samples. These sequencing kits extend the existing Promega portfolio of sample preparation and capillary electrophoresis (CE)-based STR analysis tools.
“For decades, we have anticipated and responded to the technologies that forensic laboratories need to produce reliable results,” says Tim Kupferschmid, Senior Director of Genetic Identity at Promega. “With this agreement, labs that have long benefited from Promega reagents, instrumentation and support can continue relying on us as they expand their workflows with massively parallel sequencing.”
IDseek® Massively Parallel Sequencing (MPS) Kits
All IDseek® library prep kits are built on RC-PCR technology, which enables forensic MPS library preparation in a single closed-tube reaction. The workflow is designed for the sensitivity demands of forensic casework, including degraded and low-quantity samples, and produces high on-target read yields that maximize sequencing efficiency.
“This marks an important milestone in our growth, extending our sales reach and deepening our technical capabilities to better serve customers around the world,” says Pieter van Oers, Senior Manager of Business Development – Forensics at NimaGen. “Our RC-PCR library preparation technology fundamentally simplifies the MPS workflow, eliminating the complexity that has prevented many laboratories from transitioning to MPS. With our IDseek® MPS library prep portfolio, forensic scientists can now access the power of MPS with a workflow that resembles traditional CE methods, while increasing sample safety, sensitivity and discrimination power of forensic STR testing.”
Under the new agreement, Promega will distribute more than 20 products across seven product families. Examples of applications supported include:
- Autosomal STR profiling (IDseek® OmniSTR™)
- Y-chromosomal STR profiling (IDseek® mYSTR™)
- Autosomal and Y-chromosomal STR profiling (IDseek® CombiSTR™ Plus)
- Microhaplotype analysis (IDseek® OmniHAP™)
- Identity informative SNP typing (IDseek® OmniSNP™)
- Mitochondrial DNA sequencing (IDseek® Mitochondrial HVR and Full Genome kits)
Promega Support for Forensic Laboratories
Promega has supported forensic laboratories for more than 30 years with products, instrumentation and technical expertise spanning the full workflow of human identification. For forensic laboratories evaluating the transition to MPS-based workflows, the ability to access NimaGen’s IDseek® portfolio through an established Promega relationship simplifies the path to MPS adoption. The Promega global distribution network, forensic-specific technical support infrastructure and decades of experience serving casework laboratories mean that laboratories can move into MPS with the same supplier accountability they already rely on for their CE-based workflows.
To learn more about IDseek® products distributed by Promega, click here
About Promega Corporation
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at promega.com
About NimaGen
NimaGen B.V. is a biotechnology company specializing in innovative DNA sequencing technologies for forensic applications and human identification. Headquartered in Nijmegen, The Netherlands, NimaGen holds the exclusive license for the patented Reverse Complement PCR (RC-PCR) technology, granted by the Salisbury NHS Foundation Trust, United Kingdom. The company's IDseek® product line represents the next revolution in forensic MPS, combining unmatched sensitivity, robustness, and sample safety with simplified workflows that make advanced sequencing accessible to forensic laboratories worldwide. NimaGen is part of Biolegio Holding.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260413426143/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom